New data show that patients with type 2 diabetes who start therapy based insulin, combined with a single daily dose of NovoMix ® 30 managed to reduce the HbA1c greater than treatment with insulin Glargine1 Data from a new study presented today at the annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes initiating treatment with insulin combined a daily injection of NovoMix ® 30 (biphasic insulin aspart) are able to further reduce the HbA1cque patients starting with a daily injection of insulin glargine. The treatment with NovoMix ® 30 also resulted in blood glucose levels much lower after dinner and at bedtime, compared with those patients treated with insulin glargine.1
These new data from the study OnceMix in which 480 patients with type 2 diabetes inadequately controlled by oral antidiabetic agents, participated in 15 countries. They were randomly selected for treatment based on a single daily injection of NovoMix ® 30 or insulin glargine. In total, 433 patients completed the study. The average reduction HbA1centre the baseline and the end of the study after 26 weeks was -1.41% with NovoMix ® 30 cons -1.25% with insulin glargine.1
"This study shows that NovoMix ® 30 is a particularly effective option for patients with type 2 diabetes to start insulin," said Professor Krzysztof Strojek Medical University of Silesia in Zabrze, Poland, the main author of the study. "An additional advantage of using a premixed insulin as the ® 30 from the beginning is that it is very easy to intensify the treatment as and progression of diabetes, which is both practical Patient and important in terms of long-term control of disease. " At the end of treatment, mean HbA1c was 7.08% for NovoMix ® 30 against 7.23% for insulin glargine. In the evaluation of postprandial glucose control, we observed much lower levels of plasma glucose with NovoMix ® 30 after dinner and at bedtime (NovoMix ® 30 - insulin glargine -0.52 mmol / l, 95% CI [-1.02, -0.03], p = 0.04) and (NovoMix ® 30 - insulin glargine = -0.78 mmol / l, 95% CI [-1.25, -0.31] , p <0.01) respectively.1 The incidence of hypoglycaemic episodes was very low with both treatments (6.5 episodes / year for NovoMix ® 30 against 4.8 episodes / year for insulin glargine, with three major hypoglycemic episodes in each group) and the dose final day was also low and similar with both NovoMix ® 30 with insulin glargine (0.32 + / -0.22 units / kg for NovoMix ® 30 against 0.29 + / -0.19 units / kg for insulin glargine) .1
No relevant difference a clinical point of view between the treatment groups were found in markers of cardiovascular risk, waist circumference, body mass or satisfaction of treatment.The study is an attempt OnceMix "treat-to-target" open multinational multicentre, randomized and parallel. This study was conducted in a wide range of patient populations in 15 countries and is the first direct study between NovoMix ® 30 once-daily insulin glargine and once-daily.
During the period of run-ins ", titration of glimepiride and metformin was performed, followed by randomization to a treatment period of 26 weeks. Of a total of 480 patients in total were randomly selected, 433 completed the trial and participated in the final analysis. NovoMix ® 30 (biphasic insulin aspart) is a modern premixed insulin, dual-action, indicated for the treatment of diabetes mellitus, which contains both the rapid-acting insulin (30%) and intermediate-acting insulin (70%). The compound-action rapid NovoMix ® 30 begins to exert an effect on the absorption of glucose between 0 and 10 minutes2, it can be taken just before meals, while human insulin must be administered 15-30 minutes before . The adverse side effects observed in patients treated with NovoMix ® 30 mainly doses and due to the pharmacological effect of insuline2Chez patients with type 2 diabetes, a meta-analysis showed that while the risk diurnal hypoglycemic episodes increased overall in patients treated with NovoMix ® 30, it was associated with reduced risk of nocturnal hypoglycemic episodes and overall major hypoglycaemia compared with human insulin bi-phasic 30.2
Novo Nordisk is a healthcare and the global leader in diabetes care. In addition, Novo Nordisk has a dominant position in the market for hemostasis management, growth hormone and hormones for treating menopausal disorders. Novo Nordisk manufactures and markets products and pharmaceutical services that make a difference for patients, the medical profession and society. Novo Nordisk, whose headquarters are located in Denmark, employs approximately 28,500 employees in 81 countries and sells its products in 179 countries. The B shares in Novo Nordisk are listed on stock exchanges in Copenhagen and London. Its ADRs are listed on the NYSE under the symbol "NVO"
1 Franek E, et al. Launching a single daily dose of NovoMix 30 compared with insulin glargine in patients with type 2 diabetes inadequately controlled with oral antidiabetic agents - a randomized controlled trial. 45th annual meeting of the European Association for the Study of Diabetes, Vienna, Austria, September 29 to October 2, 2009. Oral Presentation # 213
These new data from the study OnceMix in which 480 patients with type 2 diabetes inadequately controlled by oral antidiabetic agents, participated in 15 countries. They were randomly selected for treatment based on a single daily injection of NovoMix ® 30 or insulin glargine. In total, 433 patients completed the study. The average reduction HbA1centre the baseline and the end of the study after 26 weeks was -1.41% with NovoMix ® 30 cons -1.25% with insulin glargine.1
"This study shows that NovoMix ® 30 is a particularly effective option for patients with type 2 diabetes to start insulin," said Professor Krzysztof Strojek Medical University of Silesia in Zabrze, Poland, the main author of the study. "An additional advantage of using a premixed insulin as the ® 30 from the beginning is that it is very easy to intensify the treatment as and progression of diabetes, which is both practical Patient and important in terms of long-term control of disease. " At the end of treatment, mean HbA1c was 7.08% for NovoMix ® 30 against 7.23% for insulin glargine. In the evaluation of postprandial glucose control, we observed much lower levels of plasma glucose with NovoMix ® 30 after dinner and at bedtime (NovoMix ® 30 - insulin glargine -0.52 mmol / l, 95% CI [-1.02, -0.03], p = 0.04) and (NovoMix ® 30 - insulin glargine = -0.78 mmol / l, 95% CI [-1.25, -0.31] , p <0.01) respectively.1 The incidence of hypoglycaemic episodes was very low with both treatments (6.5 episodes / year for NovoMix ® 30 against 4.8 episodes / year for insulin glargine, with three major hypoglycemic episodes in each group) and the dose final day was also low and similar with both NovoMix ® 30 with insulin glargine (0.32 + / -0.22 units / kg for NovoMix ® 30 against 0.29 + / -0.19 units / kg for insulin glargine) .1
No relevant difference a clinical point of view between the treatment groups were found in markers of cardiovascular risk, waist circumference, body mass or satisfaction of treatment.The study is an attempt OnceMix "treat-to-target" open multinational multicentre, randomized and parallel. This study was conducted in a wide range of patient populations in 15 countries and is the first direct study between NovoMix ® 30 once-daily insulin glargine and once-daily.
During the period of run-ins ", titration of glimepiride and metformin was performed, followed by randomization to a treatment period of 26 weeks. Of a total of 480 patients in total were randomly selected, 433 completed the trial and participated in the final analysis. NovoMix ® 30 (biphasic insulin aspart) is a modern premixed insulin, dual-action, indicated for the treatment of diabetes mellitus, which contains both the rapid-acting insulin (30%) and intermediate-acting insulin (70%). The compound-action rapid NovoMix ® 30 begins to exert an effect on the absorption of glucose between 0 and 10 minutes2, it can be taken just before meals, while human insulin must be administered 15-30 minutes before . The adverse side effects observed in patients treated with NovoMix ® 30 mainly doses and due to the pharmacological effect of insuline2Chez patients with type 2 diabetes, a meta-analysis showed that while the risk diurnal hypoglycemic episodes increased overall in patients treated with NovoMix ® 30, it was associated with reduced risk of nocturnal hypoglycemic episodes and overall major hypoglycaemia compared with human insulin bi-phasic 30.2
Novo Nordisk is a healthcare and the global leader in diabetes care. In addition, Novo Nordisk has a dominant position in the market for hemostasis management, growth hormone and hormones for treating menopausal disorders. Novo Nordisk manufactures and markets products and pharmaceutical services that make a difference for patients, the medical profession and society. Novo Nordisk, whose headquarters are located in Denmark, employs approximately 28,500 employees in 81 countries and sells its products in 179 countries. The B shares in Novo Nordisk are listed on stock exchanges in Copenhagen and London. Its ADRs are listed on the NYSE under the symbol "NVO"
1 Franek E, et al. Launching a single daily dose of NovoMix 30 compared with insulin glargine in patients with type 2 diabetes inadequately controlled with oral antidiabetic agents - a randomized controlled trial. 45th annual meeting of the European Association for the Study of Diabetes, Vienna, Austria, September 29 to October 2, 2009. Oral Presentation # 213
No comments:
Post a Comment